問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Linkou Chang Gung Medical Foundation (在職)

Division of Thoracic Medicine

Division of Thoracic Surgery

Division of Pediatrics

Division of Infectious Disease

Division of General Internal Medicine

更新時間：2023-09-19

林鴻銓Lin, Horng-Chyuan
  • Principal Investigator
  • Clinical Trial Experience (year) 22 years 9 個月

Recruiting Trial

24Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

林鴻銓

List

58Cases

2009-10-01 - 2014-10-01

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
9Sites

Terminated9Sites

2021-07-27 - 2025-06-30

Phase II

A Phase II Study to Evaluate the Efficacy and Safety of FB825 in Adult Patients with Moderate-to-severe Allergic Asthma

  • Condition/Disease

    Allergic Asthma

  • Test Drug

    FB825

Participate Sites
17Sites

Not yet recruiting5Sites

Recruiting12Sites

2024-08-01 - 2025-12-31

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting4Sites

2009-07-01 - 2013-08-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
12Sites

Terminated12Sites

2006-11-01 - 2008-05-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Terminated5Sites

2007-09-01 - 2009-03-31

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
10Sites

Terminated10Sites

2008-10-22 - 2010-10-22

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Terminated5Sites

2014-06-30 - 2017-06-30

Phase III

Mepolizumab vs. Placebo as add-on treatment for frequently exacerbating COPD patients characterized by eosinophil level

  • Condition/Disease

    COPD

  • Test Drug

    Mepolizumab

Participate Sites
5Sites

Terminated4Sites

Study ended1Sites

徐武輝
China Medical University Hospital

Division of General Internal Medicine

1 2 3 4 5 6
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB